Status:
COMPLETED
Local Phase 4 Pan-European SMART Study
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the effect of two different maintenance doses of Symbicort Maintenance And Reliever Therapy (SMART) in adult asthmatic patients. A 6 month treatment period
Eligibility Criteria
Inclusion
- Patients at out-patient clinics
- \>18 years with a minimum of 6 months documented history of persistent asthma who have used inhaled glucocorticosteroids for at least one month and have a history of use in rapid-acting B2 agonists for symptom relief
Exclusion
- Asthma exacerbation within the last 14 days prior to study start
- subject aged \>40 years with a smoking history of \>10pack-years
- subjects with chronic obstructive lung disease or other significant respiratory disease
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
8424 Patients enrolled
Trial Details
Trial ID
NCT00463866
Start Date
March 1 2007
End Date
December 1 2008
Last Update
March 22 2010
Active Locations (817)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aalst, Belgium
2
Research Site
Aarschot, Belgium
3
Research Site
Aatrijken, Belgium
4
Research Site
Asse, Belgium